Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of the Novel Dual GIP/GLP-1 Agonist (RG7697) after Single Subcutaneous Administration in Healthy Subjects

被引：0
|
作者：
Portron, Agnes
Jadidi, Shirin
Sarkar, Neena
Dimarchi, Richard
Schmitt, Christophe
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2390-PUB
引用
收藏
页码：A624 / A624
页数：1
相关论文
共 50 条
  • [1] Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of the Novel Dual GIP/GLP-1 Agonist RG7697 in Patients with Type 2 Diabetes Mellitus
    Schmitt, Christophe
    Portron, Agnes
    Jadidi, Shirin
    Sarkar, Neena
    Dimarchi, Richard
    [J]. DIABETES, 2017, 66 : A290 - A290
  • [2] Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects
    Portron, Agnes
    Jadidi, Shirin
    Sarkar, Neena
    DiMarchi, Richard
    Schmitt, Christophe
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1446 - 1453
  • [3] Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist (HRS9531) in healthy subjects
    Wen, Q.
    He, K.
    Wei, F.
    Chen, H.
    Zhang, Y.
    Sheng, Z.
    Yin, L.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S326 - S327
  • [4] Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Dual GLP-1/Glucagon Agonist SAR425899 in Healthy Subjects and Diabetes Patients
    Tillner, Joachim
    Posch, Maximillian G.
    Hueser, Andreas
    Teichert, Lenore
    Einig, Christine
    Bergmann, Karin
    Keil, Stefanie
    Rimbault, Mathieu
    Larsen, Philip Just
    Lorenz, Martin
    [J]. DIABETES, 2016, 65 : A6 - A7
  • [5] Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral small molecule GLP-1 receptor agonist (HRS-7535) in healthy subjects
    Wu, J.
    Hu, W.
    Du, Y.
    Zhang, Q.
    Zhou, R.
    Zhang, Q.
    Qin, H.
    Ye, Z.
    Xu, Y.
    Feng, S.
    Shu, C.
    Shen, Y.
    Fan, Y.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S316 - S317
  • [6] A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
    Choi, Jae Duk
    Baek, Seungjae
    Kim, Youngmin
    Eun, Kahee
    Kwon, Se Chang
    Morrow, Linda
    Hompesch, Marcus
    Kang, Jahoon
    [J]. DIABETES, 2019, 68
  • [7] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy Subjects
    Zhang, Yuanyuan
    Xu, Xiusen
    McLendon, Kristi
    Wong, Alex H. L.
    Zhang, Yuying
    Zhang, Xujia
    [J]. DIABETES, 2024, 73
  • [8] The Pharmacokinetics, Pharmacodynamics, and Tolerability of Liraglutide, a Once-Daily Human GLP-1 Analogue, After Multiple Subcutaneous Administration in Healthy Chinese Male Subjects
    Jiang, Ji
    Zhang, Jianyan
    Jacobsen, Lisbeth V.
    Hu, Pei
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1620 - 1627
  • [9] Tolerability, Safety, and Pharmacokinetics of Once-Weekly Administration of GLP-1 Analogue in Healthy Subjects
    Xu, Michael M.
    [J]. DIABETES, 2015, 64 : A72 - A73
  • [10] A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
    Pratt, Edward J.
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah A.
    Sloop, Kyle
    Benson, Charles
    [J]. DIABETES, 2022, 71
12345